

Special Issue

Gastric Cancer: From Translational to Clinical Molecule Studies

Message from the Guest Editor

Gastric cancer is one of the most aggressive cancers. During the last decade, we observed a decline in the incidence of gastric cancer; however, no record-breaking progress in its treatment was made. There is a need for open-minded studies that will combine translational and molecular studies with clinical thinking. In my opinion, molecular classification of gastric cancer subtypes may provide guidance for targeted treatment. Moreover, the targets for immunotherapy or biological therapy should be redefined for gastric cancer. One of the most important issues is the peritoneal dissemination of gastric cancer. The questions of how to diagnose, how to prevent and how to treat are equally difficult. The role of epigenetics in the regulation of gastric carcinogenesis and progression is still not clarified. Therefore, research into these fields may be important. Last but not least is the role of the GI microbiome as a component of carcinogenesis and as a predictive factor for treatment outcomes. Another very interesting area is the impact of gastric cancer treatment on the function of immune system, the metabolism, and body composition.

Guest Editor

Dr. Antoni M. Szczepanik

1st Department of Surgery, Medical College, Jagiellonian University, Krakow, Poland

Deadline for manuscript submissions

closed (31 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/90339

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).